Semiannual Report — FY2026 H1
What STELLA PHARMA CORPORATION reported for the period from 2026-04-01 to 2027-03-31.
Filed 2026-11-13View the original on EDINET
How much it says
53Typical
What moved here
14named for the first time
Its own wording
39terms
Which filing this is
16/ 16newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the six-month interim accounting period, in the BNCT business, the company submitted to PMDA and received acceptance of an application for a partial change approval to add a contract manufacturing site as a manufacturing site, in order to rebuild a stable supply system for Steboronin. In addition, based on its partnership in China, the company advanced development activities using RWD and conducted research and development, awareness-building and clinical development support.
Komori's summary of this document, not the document's own words.53Typical
How much this filing saysA weighted roll-up of 12 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 36 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
76
Very detailed
31
Thin
94
Very detailed
62
Detailed
75
Very detailed
15
Almost nothing
68
Detailed
55
Typical
31
Thin
7
Almost nothing
55
Typical
50
Typical
R&D spend1億円Money spent making new things.
Cash left over-4億円Cash from the business, less what went into equipment.
Spent on equipment5百万円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.